50.80
+2.52%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SCI Pharmtech
Its shares trade on Taiwan Stock Exchange under the ticker 4119.TW. It has been listed since 12 August 2002. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.34bn and net income of TWD 107.4m. At that date it held total assets of TWD 6.89bn and shareholders' equity of TWD 5.39bn.
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Aug 2002
- Website
- sci-pharmtech.com.tw ↗
Leadership
Pay as last reported
- Mr. Wei-Chyun WongChairman of the Board, since 2001TWD 3.7m
- Wenzhen YangManager of Finance & Administrative
- Wenzhi ZhouGeneral Manager, Director, since 2002
- Guifang SheDeputy General Manager-BusinessTWD 3.5m
- Mr. Shiang-Li ChenDirector
- Kelin FengDirector
- Ms. Chin-Hsin HsuDirector
- Jiajun ChenIndependent Director
- Mr. Te-Cheng TuIndependent Director
- Weizhong WangIndependent Director
- Hongzhi WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SCI Pharmtech Inc has a strong research and development team that continually innovates and develops new pharmaceutical products. This allows the company to stay competitive and offer unique solutions to market demands.
- The company has established a strong reputation in the industry for its high-quality products and reliable customer service. This has led to a loyal customer base and repeat business.
- SCI Pharmtech Inc has a well-established distribution network, enabling efficient and timely delivery of its products to customers worldwide. This gives the company a competitive advantage in terms of market reach and customer satisfaction.
Weaknesses
- The company relies heavily on a few key suppliers for its raw materials, which poses a risk to its supply chain. Any disruptions in the supply of these materials could affect production and result in delays or shortages.
- SCI Pharmtech Inc has limited diversification in terms of product offerings. This makes the company vulnerable to market fluctuations and changes in customer preferences. Diversifying its product portfolio could help mitigate this weakness.
Opportunities
- The growing global healthcare industry presents significant opportunities for SCI Pharmtech Inc to expand its market presence. There is a rising demand for innovative pharmaceutical products and services, and the company can capitalize on this trend.
- Expanding into new geographic markets, particularly emerging economies, can provide SCI Pharmtech Inc with access to a larger customer base and new revenue streams. This diversification can also help mitigate risks associated with being too dependent on a single market.
Threats
- Increasing competition in the pharmaceutical industry poses a threat to SCI Pharmtech Inc's market share and profitability. The company must stay proactive in adapting to market dynamics and continuously improving its products and services to maintain its competitive position.
- Changes in government regulations and policies can significantly impact the pharmaceutical industry. SCI Pharmtech Inc needs to closely monitor and comply with these regulations to avoid any legal or compliance issues that could hinder its operations.
- Global economic uncertainties and fluctuations, such as currency exchange rates and trade disputes, may affect SCI Pharmtech Inc's financial performance. It is essential for the company to implement effective risk management strategies to mitigate these external threats.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.